Literature DB >> 17878500

Cardiovascular disease and metabolic risk factors in male patients with schizophrenia, schizoaffective disorder, and bipolar disorder.

Amy M Kilbourne1, Jaspreet S Brar, Rebecca A Drayer, Xiangyan Xu, Edward P Post.   

Abstract

The authors determined whether diagnoses of cardiovascular disease (CVD) and CVD-related conditions differed by psychiatric diagnosis among male Veterans Administration patients from the mid-Atlantic region. Among 7,529 patients (mean age: 54.5 years), the prevalence of diagnoses ranged from 3.6% (stroke) to 35.4% (hypertension). Compared with schizophrenia patients, those with bipolar disorder were 19% more likely to have diabetes, 44% more likely to have coronary artery disease, and 18% more likely to have dyslipidemia, after adjustment. Clinical suspicion for CVD-related conditions, as well as risk-modification strategies, in patients with serious mental illness should incorporate differences in prevalence across specific psychiatric diagnoses.

Entities:  

Mesh:

Year:  2007        PMID: 17878500     DOI: 10.1176/appi.psy.48.5.412

Source DB:  PubMed          Journal:  Psychosomatics        ISSN: 0033-3182            Impact factor:   2.386


  29 in total

Review 1.  Schizoaffective disorder: a review of current research themes and pharmacological management.

Authors:  Joshua T Kantrowitz; Leslie Citrome
Journal:  CNS Drugs       Date:  2011-04       Impact factor: 5.749

Review 2.  Risk of myocardial infarction and stroke in bipolar disorder: a systematic review and exploratory meta-analysis.

Authors:  M L Prieto; A B Cuéllar-Barboza; W V Bobo; V L Roger; F Bellivier; M Leboyer; C P West; M A Frye
Journal:  Acta Psychiatr Scand       Date:  2014-05-22       Impact factor: 6.392

3.  Manic/hypomanic symptom burden and cardiovascular mortality in bipolar disorder.

Authors:  Jess G Fiedorowicz; David A Solomon; Jean Endicott; Andrew C Leon; Chunshan Li; John P Rice; William H Coryell
Journal:  Psychosom Med       Date:  2009-06-26       Impact factor: 4.312

4.  Effects of an electronic reminder system on guideline-concordant treatment of psychotic disorders : Results from a pilot feasibility trial.

Authors:  Irina Franke; Sarah Thier; Anita Riecher-Rössler
Journal:  Neuropsychiatr       Date:  2016-11-07

Review 5.  Oral paliperidone: a review of its use in the management of schizoaffective disorder.

Authors:  Lily P H Yang
Journal:  CNS Drugs       Date:  2011-06-01       Impact factor: 5.749

6.  Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.

Authors:  Marc DE Hert; Christoph U Correll; Julio Bobes; Marcelo Cetkovich-Bakmas; Dan Cohen; Itsuo Asai; Johan Detraux; Shiv Gautam; Hans-Jurgen Möller; David M Ndetei; John W Newcomer; Richard Uwakwe; Stefan Leucht
Journal:  World Psychiatry       Date:  2011-02       Impact factor: 49.548

7.  Non-psychiatric hospitalization length-of-stay for patients with psychotic disorders: A mixed methods study.

Authors:  Guy M Weissinger; J Margo Brooks Carthon; Bridgette M Brawner
Journal:  Gen Hosp Psychiatry       Date:  2020-07-31       Impact factor: 3.238

8.  Quality of care for cardiometabolic disease: associations with mental disorder and rurality.

Authors:  Nancy E Morden; Ethan M Berke; Deborah E Welsh; John F McCarthy; Todd A Mackenzie; Amy M Kilbourne
Journal:  Med Care       Date:  2010-01       Impact factor: 2.983

9.  SMI life goals: description of a randomized trial of a collaborative care model to improve outcomes for persons with serious mental illness.

Authors:  Amy M Kilbourne; Margretta Bramlet; Michelle M Barbaresso; Kristina M Nord; David E Goodrich; Zongshan Lai; Edward P Post; Daniel Almirall; Lilia Verchinina; Sonia A Duffy; Mark S Bauer
Journal:  Contemp Clin Trials       Date:  2014-07-30       Impact factor: 2.226

10.  Medical and substance use comorbidity in bipolar disorder.

Authors:  David E Kemp; Keming Gao; Stephen J Ganocy; Emily Caldes; Kathryn Feldman; Philip K Chan; Carla Conroy; Sarah Bilali; Robert L Findling; Joseph R Calabrese
Journal:  J Affect Disord       Date:  2008-12-18       Impact factor: 4.839

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.